308
Views
3
CrossRef citations to date
0
Altmetric
Review

Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

, , , , & ORCID Icon
Pages 1467-1476 | Received 13 Feb 2020, Accepted 01 Jun 2020, Published online: 07 Jul 2020
 

ABSTRACT

Purpose: To provide a detailed review on the therapeutic efficacy of conbercept for the management of ocular vasculopathies.

Methods: A comprehensive literature search of various electronic databases was performed.

Results: Ocular vasculopathy is one of the major causes of visual impairment and blindness which includes a range of disorders. Vascular endothelial growth factor (VEGF) regulates angiogenesis, enhances vascular permeability, and drives the formation of neovascularization. Anti-VEGF therapy has been shown to prevent vision loss or potentially improve vision in patients with exudative or neovascular retinal disease. The most recent anti-VEGF drug in China is conbercept. In the USA and Europe, bevacizumab is the most recently approved anti-VEGF agent.

Conclusions: Conbercept serves as another anti-VEGF option for patients with neovascular AMD and other retinal vascular disorders. There have not been many clinical trials that study conbercept as compared with other currently available anti-VEGF drugs. There is a need for large-scale, well-designed, randomized clinical trials to ensure its long-term safety and efficacy and to determine if it has any advantages over other anti-VEGF agents.

Declaration of conflicting interests

The authors report no conflicts of interest.

Additional information

Funding

Supported by Hebei Provincial Department of Science and Technology, Shijiazhuang, Hebei, China [grant No. 182777112D].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.